

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 5, 2001.

LAW OFFICES OF JONATHAN ALAN QUINE

By Alexander Allison  
Alexandra Allison

Attorney Docket No. 31-001100US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Anders Hjelholt Pedersen, et al.

Application No.: 09/782,587

Filed: February 12, 2001

For: FACTOR VII OR VIIA-LIKE  
MOLECULES

Examiner: Unassigned

Art Unit: Unassigned

COMUNICATION TO THE EXAMINER  
REGARDING SEQUENCE LISTING

Box Missing Parts  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The accompanying sequence listing is be submitted in response to the missing parts dated May 9, 2001. Please amend the specification as follows:

Page 45, lines 7-20:

The identity of the specific tag to be used is not critical as long as the tag is capable of being expressed with the polypeptide and is capable of being immobilised on a suitable surface or carrier material. A number of suitable tags are commercially available, e.g., from Unizyme Laboratories, Denmark. For instance, the tag can consist of any of the following sequences: (SEQ ID NOS 12-16, respectively)

His-His-His-His-His

Met-Lys-His-His-His-His-His

Met-Lys-His-His-Ala-His-His-Gln-His-His

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-Gln

or any of the following: (SEQ ID NOS 17-19, respectively)

EQKLI SEEDL (a C-terminal tag described in Mol. Cell. Biol. 5:3610-16, 1985)

COPY

Anders Hjelholt Pedersen, et al.  
Application No.: 09/782,587  
Page 2

COPY

DYKDDDDK (a C- or N-terminal tag)

YPYDVPDYA

On page 67, lines 27-30:

A vector for the cloning of the generated PCR product encompassing the expression cassette for native human blood coagulation factor VII was prepared by cloning the intron from pCINeo (Promega). The synthetic intron from pCI-Neo was amplified using standard PCR conditions as described above and the primers: (SEQ ID NOS 5-6, respectively).

On page 68, lines 14-20:

For example, in order to change the codons for R315 and V317 to the codons for N315 and T317 the following primers were used pair wise for the primary PCR's: (SEQ ID NOS 7-8, respectively)

CBProFpr216: 5'-CTTAAGGATCCGCCACCATGGTCAGCCAG-3' and

CBProFpr229: 5'-GGAGTCCCCGGTTTGTTGGACTGCTGC-3',

and (SEQ ID NOS 9-10, respectively)

CBProFpr221: 5'-ACTTAAGCTTTATCAAGGGA-3' and

CBProFpr228: 5'-GCAGCAGTCCAACAAAACCGGGGACTCC-3'.

On page 68, lines 26-29:

Furthermore, in cases where the introduced mutation(s) were sufficiently close to a unique restriction endo-nuclease site in the expression plasmid variant genes were constructed using construction procedure encompassing a single PCR step and a subsequent cloning. For instance, the substitution K143N+N145T was introduced by use of the PCR primers: (SEQ ID NOS 11 & 9, respectively)

#### REMARKS

A complete replacement sequence listing is submitted in both paper and electronic format, as well as a marked copy of the relevant portion of the specification.

Anders Hjelholt Pedersen, et al.  
Application No.: 09/782,587  
Page 3

COPY

**CONCLUSION**

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

LAW OFFICES OF  
JONATHAN ALAN QUINE  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Respectfully submitted,



Jonathan Alan Quine  
Reg. No. 41,261

COPY

**MARKED COPY OF RELEVANT PORTION OF THE SPECIFICATION FOR  
USSN 09/782,587**

Insertions are indicated by underlining of the character.

Page 45, lines 7-20:

The identity of the specific tag to be used is not critical as long as the tag is capable of being expressed with the polypeptide and is capable of being immobilised on a suitable surface or carrier material. A number of suitable tags are commercially available, e.g., from Unizyme Laboratories, Denmark. For instance, the tag can consist of any of the following sequences: (SEQ ID NOS 12-16, respectively)

His-His-His-His-His

Met-Lys-His-His-His-His-His

Met-Lys-His-His-Ala-His-His-Gln-His-His

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln

or any of the following: (SEQ ID NOS 17-19, respectively)

EQKLI SEEDL (a C-terminal tag described in Mol. Cell. Biol. 5:3610-16, 1985)

DYKDDDDK (a C- or N-terminal tag)

YPYDVPDYA

On page 67, lines 27-30:

A vector for the cloning of the generated PCR product encompassing the expression cassette for native human blood coagulation factor VII was prepared by cloning the intron from pCINeo (Promega). The synthetic intron from pCI-Neo was amplified using standard PCR conditions as described above and the primers: (SEQ ID NOS 5-6, respectively).

On page 68, lines 14-20:

For example, in order to change the codons for R315 and V317 to the codons for N315 and T317 the following primers were used pair wise for the primary PCR's: (SEQ ID NOS 7-8, respectively)

CBProFpr216: 5'-CTTAAGGATCCCGCCACCATGGTCAGCCAG-3' and

CBProFpr229: 5'-GGAGTCCCCGGTTTGTGGACTGCTGC-3',

COPY

and (SEQ ID NOS 9-10, respectively)

CBProFpr221: 5'-ACTTAAGCTTTATCAAGGGA-3' and

CBProFpr228: 5'-GCAGCAGTCCAACAAAACCAGGGGACTCC-3'.

On page 68, lines 26-29:



Furthermore, in cases where the introduced mutation(s) were sufficiently close to a unique restriction endo-nuclease site in the expression plasmid variant genes were constructed using construction procedure encompassing a single PCR step and a subsequent cloning. For instance, the substitution K143N+N145T was introduced by use of the PCR primers: (SEQ ID NOS 11 & 9, respectively)

**LegalStar USPTO<sup>TM</sup> Acknowledgment Postcard**For Use With IP LegalForm Electronic Forms  
Product #AP001 (Call 800-605-3360 to Reorder)**COPY**SERIAL NO.: 09/782,587 DATE FILED: 02/12/01 DKT. NO.: 0212us310 ATTY.: JRP

TITLE: - Factor VII or VIIa-like Molecules

APPLICANT: Anders Hjelholt Pedersen et al. DATE MAILED/HAND DELIVERED: July 1, 2002 CERTIFICATE OF MAILING  EXPRESS MAIL LABEL NO. \_\_\_\_\_**THE U.S. PATENT AND TRADEMARK OFFICE ACKNOWLEDGES RECEIPT OF:**

- pp Spec  pp. Claims  Abstract  Amendment  
 Auth. To Charge Deposit Account No. 50-0990  Rule 1.53(b) of USSN  
 Fees \$  Rule 1.53(c) of USSN  
 Declaration  Signed  Unsigned  Rule 1.53(d) of USSN  
 Assignment (w/ cover letter)  Petition  
 Power of Attorney  Appointment of Agent  
 Informal Drawings  Sheets  Transmittal Return postcard;  
 Formal Drawings  Sheets  
 Information Disclosure Statement  (INT. PROPERTY)  
 Form SB/08 or 1449  1 pp. & References  Notice of Appeal  
 Paper Sequence Listing  Pages  Appeal Brief, plus 2 copies  
 Disk Containing Sequence Listing  Issue Fee Transmittal  
 Declaration/Affidavit



F-468  
**OFFICIAL****MAXYGEN**

Intellectual Property  
**515 Galveston Drive**  
**Redwood City, California 94063 USA**  
 Telephone: (650) 298-5300  
 Facsimile: (650) 298-5446

**FACSIMILE COVER SHEET**Total No. of Page(s): 30 (including this sheet)

WARNING: THIS FACSIMILE MESSAGE AND ANY ACCOMPANYING DOCUMENTS ARE INTENDED ONLY FOR THE USE OF THE ADDRESSEE INDICATED. INFORMATION THAT IS PRIVILEGED OR OTHERWISE CONFIDENTIAL MAY BE CONTAINED HEREIN. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, COPYING, REVIEW OR USE OF THIS MESSAGE, DOCUMENTS OR INFORMATION CONTAINED HEREIN IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS MESSAGE IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE OR FACSIMILE AND MAIL THE ORIGINAL TO US AT THE ADDRESS TO THE LEFT. WE WILL REIMBURSE ANY REASONABLE EXPENSES ACTUALLY INCURRED. THANK YOU.

**RECEIVED  
CENTRAL FAX CENTER**

DEC 10 2003

**CERTIFICATE OF FACSIMILE TRANSMITTAL  
UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, facsimile no. (703) 872-9306, on December 10, 2003

By:

Joanne R. Petithory

Joanne R. Petithory

Attorney Docket No: 0212us310

In re application of:

A.H. Pedersen, et al.

Examiner: Teller, Roy R.

Application No.: 09/782,587

Art Unit: 1654

Filed: February 12, 2001

**AMENDMENT**

For: Factor VII or VIIa - Like Molecules

**TO BE MADE OF OFFICIAL RECORD**Enclosed in this transmission are:

- (1 page) This Cover Sheet
- (1 page) Transmittal Sheet
- (2 pages) Petition for one-month extension of time, plus 1 copy
- (17 pages) Amendment
- (3 pages) Copy of previously-filed IDS and Form 1449 originally submitted July 1, 2002
- (1 page) Copy of date-stamped receipt postcard for the above-noted IDS
- (5 pages) Copy of previously-filed Communication originally submitted July 6, 2001

30 pages total


---

Please contact Joanne Petithory at (650) 298-5452 if you have any problems receiving this transmission.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/782,587
		Filing Date	February 12, 2001
		First Named Inventor	A.H. Pedersen
		Group Art Unit	1654
		Examiner Name	Teller, Roy R.
Total Number of Pages in This Submission	30	Attorney Docket Number	0212us310

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response ( 17 pp. )	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request plus 1 copy	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s). (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<ul style="list-style-type: none"> <li>• copy of IDS and form 1449 submitted July 1, 2002 (3 pp.)</li> <li>• copy of postcard (1 p.)</li> <li>• copy of Communication submitted July 6, 2001 (5 pp.)</li> <li>• fax cover sheet (1 p.)</li> </ul>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

### Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0990 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

### Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Joanne R. Petithory Reg. No. 42,995	
Signature		
Date	Dec 10, 2003	

### CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, facsimile no. (703) 872-9306 on the date shown below:

Typed or printed name	Joann R. Petithory		
Signature		Date	Dec. 10, 2003